This is a working overview of stability testing, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-06-06 and is reviewed periodically as new material appears.
Quality control for hydrolysate ingredients focuses on identity, purity, and consistency, with specifications that may include total protein, hydrolysis level, molecular weight distribution, microbiological limits, heavy metals, and allergen labeling. In some jurisdictions, partially and extensively hydrolyzed formulas are regulated as foods for special dietary uses or as infant formula ingredients. Regulatory status varies by country and intended use. Documentation such as certificates of analysis, safety data sheets, and method validation records supports traceability. Open questions remain about standardizing hydrolysis measurements across suppliers and laboratories.
Testing hydrolysate powders typically begins with proximate analysis for moisture, ash, fat, and total nitrogen. Protein content is calculated from nitrogen using a conversion factor, most often Kjeldahl or Dumas combustion. Peptide size distribution is assessed by size-exclusion chromatography, reversed-phase HPLC, or mass spectrometry. Sodium dodecyl sulfate polyacrylamide gel electrophoresis can show residual intact protein bands. Free amino groups may be quantified by colorimetric assays to estimate cleavage extent, though different methods and laboratories are not always directly comparable.
Dry hydrolysate powders are generally stable when kept cool, dry, and sealed, while moisture uptake can cause caking, Maillard browning, and loss of solubility. Higher temperatures accelerate these changes and may alter flavor. Recommended storage conditions often fall between 15 and 25 degrees Celsius with relative humidity below 60 percent. Once reconstituted, liquid hydrolysate solutions support microbial growth and may develop bitterness or haze over time. Packaging in moisture-barrier containers with desiccants helps maintain quality during transport and warehouse storage.
Quality control focuses on degree of hydrolysis, molecular weight distribution, protein content, moisture, ash, and microbial limits. Degree of hydrolysis is commonly calculated from the number of cleaved peptide bonds relative to total peptide bonds. Size-exclusion chromatography and mass spectrometry can describe peptide size ranges, while amino acid analysis quantifies composition. Standard methods from dairy science organizations are often used, though no single method captures every functional property. Results are therefore reported alongside processing conditions.
Hydrolysates are generally stable as dry powders but can absorb moisture and undergo browning during warm storage. The bitter taste of some hydrolysates arises from hydrophobic peptides exposed by cleavage, and it varies with enzyme choice and degree of hydrolysis. Reduced allergenicity is sometimes claimed, but residual IgE-binding peptides may remain, especially in partial hydrolysates. Regulatory frameworks treat extensively hydrolyzed and partially hydrolyzed products differently, and labeling rules vary by country. More research is needed on how specific peptide profiles relate to clinical outcomes.
| Property | Value | Notes |
|---|---|---|
| Moisture content | ≤5% typical | Higher moisture promotes caking and browning |
| pH (5% solution) | 6.0–7.5 typical | Varies with hydrolysis and neutralization |
| Ash content | 1–8% | Depends on demineralization and neutralization salts |
| Microbiological limit | Total aerobic count <10^4 CFU/g typical | Specifications vary by grade and market |
| Shelf life | 12–24 months unopened | Cool, dry storage extends stability |
Quality control for whey protein hydrolysate begins with verifying protein content, moisture, ash, and fat using standard food analysis methods. Total nitrogen by Kjeldahl or Dumas combustion gives an estimate of protein, often calculated with a dairy-specific conversion factor. Amino acid analysis after acid hydrolysis quantifies individual residues but destroys tryptophan and may convert glutamine and asparagine. The extent of peptide bond cleavage is usually estimated by measuring free amino groups, soluble nitrogen, or trichloroacetic acid-soluble peptides. These tests are operationally defined and can give different results across laboratories.
Peptide size distribution is central to product characterization because biological and functional effects often depend on molecular weight. Size-exclusion chromatography, reversed-phase high-performance liquid chromatography, and capillary electrophoresis can separate peptides by size or hydrophobicity. Mass spectrometry provides sequence-level information and can detect marker peptides, though it is less common for routine lot release. For allergen control, enzyme-linked immunosorbent assays estimate residual intact protein or specific milk proteins, but results depend on antibody recognition and may not detect small peptides. No single method captures the full composition.
Quality control for hydrolyzed whey protein focuses on composition, peptide size, and batch consistency. Protein content is commonly measured by Kjeldahl or combustion analysis, while moisture and ash are determined by gravimetric methods. Peptide molecular weight distribution is often assessed by size exclusion chromatography or mass spectrometry. The extent of hydrolysis can be estimated by titration, trinitrobenzenesulfonic acid assays, or formol titration. Because hydrolysis produces a complex mixture, no single test captures every relevant property, and laboratories often combine several methods.
Allergen testing is relevant because whey is a milk-derived ingredient. Immunoassays can detect residual milk proteins, but hydrolysis may alter or destroy antibody-binding sites, leading to false negatives or underestimation. Liquid chromatography with tandem mass spectrometry can identify specific peptide markers and is less dependent on intact protein epitopes. Regulatory labeling rules for milk allergens vary by country, and a product described as hydrolyzed is not automatically exempt from allergen declaration. For infants, specialized formulas require strict control of protein molecular weight and sterility, which adds testing beyond routine composition.
Physical properties such as particle size, bulk density, and reconstitution behavior affect handling and finished product quality. Water activity and moisture content influence shelf life; high moisture can promote caking, browning, and microbial growth. Color is monitored because Maillard reactions between peptides and reducing sugars can darken the powder during storage. Taste panels and instrumental methods may assess bitterness, which is a common challenge for hydrolysates. Specifications often include limits for heavy metals, microbiological counts, and residual fat, depending on the intended market.
== Drug nomenclature for radiopharmaceuticals == As with other pharmaceutical drugs, there is standardization of the drug nomenclature for radiopharmaceuticals, although various standards coexist. The International Nonproprietary Name (INN) gives the base drug name, followed by the radioisotope (as mass number, no space, element symbol) in parentheses with no superscript, followed by the ligand (if any). It is common to see square brackets and superscript superimposed onto the INN name, because chemical nomenclature (such as IUPAC nomenclature) uses those. The United States Pharmacopeia (USP) name gives the base drug name, followed by the radioisotope (as element symbol, space, mass number) with no parentheses, no hyphen, and no superscript, followed by the ligand (if any). The USP style is not the INN style, despite their being described as one and the same in some publications (e.g., AMA, whose style for radiopharmaceuticals matches the USP style). The United States Pharmacopeial Convention is a sponsor organization of the USAN Council, and the USAN for a given drug is often the same as the USP name.
Since June 20, 1979, the FDA has received many questions about Good Laboratory Practice (GLP) regulations (21 CFR 58). The responses to these inquiries are stored in the Dockets Management Branch (HFA-305) and shared with the Agency's Bioresearch Monitoring (BIMO) program managers and district offices to ensure consistency. Consequently, the US FDA published the 1981 Questions & Answers - Good Laboratory Practice Regulations document to consolidate and clarify these responses. This Q&A document categorizes responses by specific GLP provisions to make them more useful for both the FDA headquarters and field offices. The FDA has signed a memorandum of understanding (MOU) with Canada, France, Germany, Italy, Japan, The Netherlands, Sweden, and Switzerland to enhance cooperation on good laboratory practice (GLP) for nonclinical laboratory studies supporting product approvals, aiming to facilitate information exchange and inspections for regulatory oversight. Proposed amendments were published in the Federal Register on August 24, 2016, which aimed to require a comprehensive quality system approach known as a GLP Quality System to enhance the current quality system approach for nonclinical laboratory studies. This system would be mandatory for safety and toxicity studies that support or are intended to support applications or submissions for products regulated by the FDA.
Opioids are among the world's oldest known drugs. The earliest known evidence of Papaver somniferum in a human archaeological site dates to the Neolithic period around 5,700–5,500 BCE. Its seeds have been found at Cueva de los Murciélagos in the Iberian Peninsula and La Marmotta in the Italian Peninsula. Use of the opium poppy for medical, recreational, and religious purposes can be traced to the fourth century BC, when ideograms on Sumerians clay tablets mention the use of "Hul Gil", a "plant of joy". Opium was known to the Egyptians, and is mentioned in the Ebers Papyrus as an ingredient in a mixture for the soothing of children, and for the treatment of breast abscesses. Opium was also known to the Greeks. It was valued by Hippocrates (c. 460 – c. 370 BC) and his students for its sleep-inducing properties, and used for the treatment of pain. The Latin saying "Sedare dolorem opus divinum est", trans. "Alleviating pain is the work of the divine", has been variously ascribed to Hippocrates and to Galen of Pergamum. The medical use of opium is later discussed by Pedanius Dioscorides (c. 40 – 90 AD), a Greek physician serving in the Roman army, in his five-volume work, De Materia Medica. During the Islamic Golden Age, the use of opium was discussed in detail by Avicenna (c. 980 – June 1037 AD) in The Canon of Medicine. The book's five volumes include information on opium's preparation, an array of physical effects, its use to treat a variety of illness, contraindications for its use, its potential danger as a poison and its potential for addiction.
== Adverse effects == In the clinical trials that lead to emapalumab's FDA approval, the most commonly reported adverse effects were infections (56%), high blood pressure (41%), infusion reactions (27%), and fever (24%). Serious adverse effects occurred in about half of the subjects studied in the clinical trial that led to its FDA approval.
Sources: en.wikipedia.org
Silica gel particles have a high surface area for interactions to take place, either with solutes or bonding with ligands. Silica gel does not react with many types of solvents and analytes. Silica gel can be modified with various functional groups. Silica gel is cheap. Silica gel particles are easy to engineer into specific diameters, shapes, pore sizes, etc. The silica particle can have different shapes. The particle can be fully solid ("monolithic" or "fused"), full of holes ("porous"), or have a solid core and a porous shell ("superficially porous"). The particle can have different diameters. The pores can have different diameters. The United States Pharmacopoeia (USP) has classified HPLC columns by L# types. The most popular column in this classification is an octadecyl carbon chain (C18)-bonded silica (USP classification L1). This is followed by C8-bonded silica (L7), pure silica (L3), cyano-bonded silica (CN) (L10) and phenyl-bonded silica (L11). Note that C18, C8 and phenyl are dedicated reversed-phase stationary phases, while CN columns can be used in a reversed-phase mode depending on analyte and mobile phase conditions. Not all C18 columns have identical retention properties. Surface functionalization of silica can be performed in a monomeric or a polymeric reaction with different short-chain organosilanes used in a second step to cover remaining silanol groups (end-capping). While the overall retention mechanism remains the same, subtle differences in the surface chemistries of different stationary phases will lead to changes in selectivity.
5S rRNA is transcribed by RNA polymerase III. The 18S rRNA in most eukaryotes is in the small ribosomal subunit, and the large subunit contains three rRNA species (the 5S, 5.8S and 28S in mammals, 25S in plants, rRNAs). In flies, the large subunit contains four rRNA species instead of three with a split in the 5.8S rRNA that presents a shorter 5.8S subunit (123 nt) and a 30 nucleotide subunit named the 2S rRNA. Both fragments are separated by an internally transcribed spacer of 28 nucleotides. Since the 2S rRNA is small and highly abundant, its presence can interfere with construction of sRNA libraries and compromise the quantification of other sRNAs. The 2S subunit is retrieved in fruit fly and dark-winged fungus gnat species but absent from mosquitoes. The tertiary structure of the small subunit ribosomal RNA (SSU rRNA) has been resolved by X-ray crystallography. The secondary structure of SSU rRNA contains 4 distinct domains—the 5', central, 3' major and 3' minor domains. A model of the secondary structure for the 5' domain (500-800 nucleotides) is shown.
Arthur 'Blaine' Bowman (born 1946 in Ogden, Utah, USA) is a leading proponent of ion chromatography, who has served variously as chairman, president, chief executive officer, and director of Dionex Corporation, a manufacturer of analytical instruments. Bowman received the 2015 Pittcon Heritage Award in recognition of his contributions to the field of ion chromatography.
Sources: en.wikipedia.org
Keep the powder sealed in a cool, dry place away from direct sunlight and strong odors. Typical targets are 15 to 25 degrees Celsius and low relative humidity. After opening, use within the manufacturer's recommended period.
Size-exclusion chromatography and mass spectrometry provide molecular weight or mass information. Electrophoresis can reveal intact protein bands and larger fragments. No single method captures the complete peptide profile.
Not always, because assays and calculation methods differ. Values may reflect free amino groups, pH change, or nitrogen solubility. Comparisons require method details and reference standards.
Degree of hydrolysis is often estimated by quantifying free amino groups or by titrating cleaved peptide bonds. It can also be inferred from molecular weight distribution using chromatography. Values are operationally defined, so comparisons require the same method and conditions.